IntelGenx, through its cutting edge formulation platforms, has developed a broad and diverse product portfolio, including products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products.


IntelGenx has three proprietary delivery platforms, including an immediate release oral film, VersaFilm™, a mucoadhesive tablet, AdVersa™ and multilayer controlled release tablet, VersaTab™. IntelGenx has an aggressive product development initiative that primarily focuses on addressing unmet market needs. Our rapidly growing product pipeline consists of products at various stages of development from inception to commercialization.


We are proud of our ability to provide and develop a wide and highly diverse range of products catering for present and future commercial needs. Our highly qualified and diversified team provides expertise and services in the following area: formulation development, analytical testing and method development, scale up and technology transfer, manufacturing support, regulatory, clinical research and intellectual properties.


08/10/2015 - IntelGenx Reports Q2 and First Six Months 2015 Results and Provides Corporate Development Update

SAINT LAURENT, QUEBEC, August 10, 2015 – IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced financial results for the three and six months ended June 30, 2015 and provided an update on operational developments. All amounts are in U.S. Dollars unless otherwise stated.

08/06/2015 - IntelGenx to Provide Second Quarter 2015 Update on August 10, 2015

Saint Laurent, Quebec – (Newsfile Corp. – August 06, 2015) – IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (“IntelGenx”), a leading drug delivery company focused on the development of novel rapidly disintegrating delivery systems as well as oral controlled-release products, today announced that it will release its second quarter 2015 results for the period ended June 30, 2015, on August 10, 2015 at the close of the financial markets.

08/05/2015 - IntelGenx Announces Appointment of New Director

Saint Laurent, Quebec-(August 5, 2015) – IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that Mr. Clemens Mayr has accepted his appointment to serve on the Company’s Board of Directors.

Read More News